Business
EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray
EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Mosanna Therapeutics ("the Company"). The clinical-stage biotech company headquartered in Basel, Switzerland, is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea (OSA) that aims to restore the body's natural airway control. The financing was led by EQT Life Sciences and Pivotal bioVenture Partners, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investor
About this update from Eqt Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"Series A Funding will be used to advance Mosanna's nasal spray therapy through Phase 2 Clinical Trials","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Biotech veteran David Weber has been appointed CEO to lead the company through clinical development","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Obstructive sleep apnea (OSA) affects nearly 1 billion people globally, with the majority undiagnosed and underserved with current treatment options","length":148,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":353,"olType":false},{"type":"text","content":"STOCKHOLM, June 9, 2025 /PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Mosanna Therapeutics ("the Company"). The clinical-stage biotech company headquartered in Basel, Switzerland, is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea (OSA) that aims to restore the body's natural airway control. The financing was led by EQT Life Sciences and Pivotal bioVenture Partners, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures as well as Supermoon Capital and High-Tech Gründerfonds (HTGF).","length":663,"tagName":"p"},{"type":"text","content":""What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a neurological and muscular dysfunction rather than a purely mechanical issue" said Daniela Begolo, Ph.D., Managing Director at EQT Life Sciences, who will be joining the Board of Directors. "MOS118 is the first therapy with the potential to restore the body's natural airway reflex with the simplicity of a nasal spray. MOS118 has the potential to dramatically improve adherence and outcomes in a patient population that has long been underserved."","length":569,"tagName":"p"},{"type":"text","content":"OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents. Despite OSA's prevalence, treatment has largely focused on mechanical solut...